FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980142010> ?p ?o ?g. }

• W2980142010 endingPage "2116" @default.
• W2980142010 startingPage "2116" @default.
• W2980142010 abstract "Abstract Introduction: With the development of novel therapeutic agents, more than 30% of patients with multiple myeloma (MM) achieve complete response (CR) as defined by the International Myeloma Working Group (IMWG). However, most patients that achieve CR ultimately die due to relapse, suggesting the presence of minimal residual disease (MRD) in these patients. Multicolor flow cytometry (MFC) allows the detection of < 10-4 clonal plasma cells in normal bone marrow cells and has been used for detecting MRD after treatment. MFC-defined immunophenotypic response (IR) has emerged as a more relevant prognostic factor in patients with MM. However, the relevance of the prognostic impact of IR and the normalization of serum free light chain (sFLC) ratio remain unclear. We retrospectively analyzed the impact of IR, conventional immunofixation negative CR (CR), and CR plus FLC kappa/lambda (k/l) normal CR (sCR) on the prognosis of 83 patients with MM who obtained better than very good partial response (VGPR) at Kameda Medical Center, Kamogawa, Japan. Methods: Among the 164 patients treated at our hospital between April 2005 and July 2014, 83 patients that achieved more than VGPR were included in this study. The study population consisted of 49 males and 34 females with a median age of 71 years. All patients received at least one course of novel agent-containing therapeutic regimen. Autologous stem cell transplantation was performed 43 patients. Maintenance treatment was not systematically given, but patients failed to achieve CR continued to receive treatment until CR was obtained. Treatment responses were assessed using the IMWG criteria, and the best response to treatment during the course of disease was assessed by simultaneous analysis by serum immunofixation, sFLC measurements, and MFC analysis of bone marrow plasma cells. Identification of plasma cells MFC requires at least two markers (CD38 and either CD45 or CD138) by single-tube 6-color flow-cytometry. Neoplastic plasma cells were further identified from normal plasma cell based on differential expression of CD19 and CD45 characteristics. Patients were considered MRD negative (IR) when ≤ 50 neoplastic plasma cells were detected by MFC in the bone marrow samples at the sensitivity limit of 10-4. Overall survival (OS) and Time to next treatment (TNT) differences between curves were calculated by two-sided log-rank test. Subjects were classified into three categories, i.e., CR with MRD positive or negative and VGPR, and TNT and OS were compared between groups. Results: At a median follow-up of 44.8 months, 83 patients obtained better than VGPR, ie; CR, 55 patients, VGPR, 28 patients. Among the 55 patients who obtained CR, normalization of sFLC k/l and IR were achieved in 48 (88%) and 28 (51%) patients, respectively. Conversely, normal sFLC k/l ratio was achieved in 66 patients, 50 were in CR and 16 were in VGPR. IR was obtained in 34/83 (41%) patients. Among 48 CR patients with normal sFLC k/l (stringent CR), IR was obtained 27 patients (56%). All of the 7 CR patients with abnormal sFLC k/l (non-stringent CR) did not achieve IR. Kaplan–Meier estimated 3- and 5-year OS were 94% and 80% in patients with CR, 90% and 71% in patients with VGPR. No significant differences were observed at 3- and 5-year OS between patients achieved CR and VGPR. Among the patients with VGPR or better response, patients with IR showed significantly longer TNT compared to those without IR. However, The patients who achieved CR and IR showed significantly longer TNT compared to those with VGPR (P=0.004), but CR patients without IR showed similar TNT curve with VGPR patients. Patients with both CR and IR showed longer TNT than those CR but without IR, although difference between the 2 groups was marginally significant (P=0.06). Although, patients with IR and normal sFLC showed significantly longer TNT compared to those with VGPR, it was not translated to longer OS reflecting the continuous maintenance treatment for VGPR patients. Conclusion: Although both achievement of CR, normalization of sFLC k/l, and IR appeared to confer on longer TNT and OS, obtaining IR seems to have greater implications for longer survival compared to CR or FLC k/l normalization. MFC analysis is a rapid, affordable, and easy performable method for measurement of MRD, and IR could be considered as a goal of treatment for patients with MM. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare." @default.
• W2980142010 created "2019-10-18" @default.
• W2980142010 creator A5010746455 @default.
• W2980142010 creator A5022626654 @default.
• W2980142010 creator A5025340212 @default.
• W2980142010 creator A5048163457 @default.
• W2980142010 creator A5049127192 @default.
• W2980142010 creator A5064026305 @default.
• W2980142010 creator A5067504416 @default.
• W2980142010 creator A5089203135 @default.
• W2980142010 date "2014-12-06" @default.
• W2980142010 modified "2023-10-16" @default.
• W2980142010 title "Prognostic Impact of Immunophenotypic Response and Normalization of Serum Free Light Chain Among Patients with Multiple Myeloma" @default.
• W2980142010 doi "https://doi.org/10.1182/blood.v124.21.2116.2116" @default.
• W2980142010 hasPublicationYear "2014" @default.
• W2980142010 type Work @default.
• W2980142010 sameAs 2980142010 @default.
• W2980142010 citedByCount "0" @default.
• W2980142010 crossrefType "journal-article" @default.
• W2980142010 hasAuthorship W2980142010A5010746455 @default.
• W2980142010 hasAuthorship W2980142010A5022626654 @default.
• W2980142010 hasAuthorship W2980142010A5025340212 @default.
• W2980142010 hasAuthorship W2980142010A5048163457 @default.
• W2980142010 hasAuthorship W2980142010A5049127192 @default.
• W2980142010 hasAuthorship W2980142010A5064026305 @default.
• W2980142010 hasAuthorship W2980142010A5067504416 @default.
• W2980142010 hasAuthorship W2980142010A5089203135 @default.
• W2980142010 hasConcept C126322002 @default.
• W2980142010 hasConcept C141071460 @default.
• W2980142010 hasConcept C143998085 @default.
• W2980142010 hasConcept C159654299 @default.
• W2980142010 hasConcept C163864487 @default.
• W2980142010 hasConcept C203014093 @default.
• W2980142010 hasConcept C2776364478 @default.
• W2980142010 hasConcept C2778808339 @default.
• W2980142010 hasConcept C2779050716 @default.
• W2980142010 hasConcept C2779823535 @default.
• W2980142010 hasConcept C2780007613 @default.
• W2980142010 hasConcept C2780073493 @default.
• W2980142010 hasConcept C2908647359 @default.
• W2980142010 hasConcept C36394416 @default.
• W2980142010 hasConcept C542903549 @default.
• W2980142010 hasConcept C71924100 @default.
• W2980142010 hasConcept C90924648 @default.
• W2980142010 hasConcept C99454951 @default.
• W2980142010 hasConceptScore W2980142010C126322002 @default.
• W2980142010 hasConceptScore W2980142010C141071460 @default.
• W2980142010 hasConceptScore W2980142010C143998085 @default.
• W2980142010 hasConceptScore W2980142010C159654299 @default.
• W2980142010 hasConceptScore W2980142010C163864487 @default.
• W2980142010 hasConceptScore W2980142010C203014093 @default.
• W2980142010 hasConceptScore W2980142010C2776364478 @default.
• W2980142010 hasConceptScore W2980142010C2778808339 @default.
• W2980142010 hasConceptScore W2980142010C2779050716 @default.
• W2980142010 hasConceptScore W2980142010C2779823535 @default.
• W2980142010 hasConceptScore W2980142010C2780007613 @default.
• W2980142010 hasConceptScore W2980142010C2780073493 @default.
• W2980142010 hasConceptScore W2980142010C2908647359 @default.
• W2980142010 hasConceptScore W2980142010C36394416 @default.
• W2980142010 hasConceptScore W2980142010C542903549 @default.
• W2980142010 hasConceptScore W2980142010C71924100 @default.
• W2980142010 hasConceptScore W2980142010C90924648 @default.
• W2980142010 hasConceptScore W2980142010C99454951 @default.
• W2980142010 hasIssue "21" @default.
• W2980142010 hasLocation W29801420101 @default.
• W2980142010 hasOpenAccess W2980142010 @default.
• W2980142010 hasPrimaryLocation W29801420101 @default.
• W2980142010 hasRelatedWork W119914118 @default.
• W2980142010 hasRelatedWork W2036702941 @default.
• W2980142010 hasRelatedWork W2083417291 @default.
• W2980142010 hasRelatedWork W2148758597 @default.
• W2980142010 hasRelatedWork W2329039810 @default.
• W2980142010 hasRelatedWork W2397999415 @default.
• W2980142010 hasRelatedWork W2577795541 @default.
• W2980142010 hasRelatedWork W2966756439 @default.
• W2980142010 hasRelatedWork W2980142010 @default.
• W2980142010 hasRelatedWork W2989947979 @default.
• W2980142010 hasVolume "124" @default.
• W2980142010 isParatext "false" @default.
• W2980142010 isRetracted "false" @default.
• W2980142010 magId "2980142010" @default.
• W2980142010 workType "article" @default.